Clinical trials: Stage II Breast Carcinoma
Metastatic Breast Cancer
Phase II Pilot Study Assessing Efficacy of a Cisplatin - Metronomic Cyclophosphamide Treatment in Patients With Metastatic Triple Negative Breast Cancer Resistant to Anthracyclines and Taxanes
To evaluate response rate of cisplatin - metronomic cyclophosphamide treatment.
- Trial name
- NCT01910870
- Testing
- Cisplatin, Metronomic Cyclophosphamide
- Where
- France
- Volunteers
- 4 people
- Sponsor
- Centre Jean Perrin
Breast Cancer
Capecitabine 7/7 Schedule With Neratinib in Patients With Metastatic HER2-Positive Breast Cancer
This is a phase l/II study. The purpose of this study is to test the safety of the study drug neratinib in combination with a standard chemotherapy drug called capecitabine at different doses to find out what effects, if any, it…
- Trial name
- NCT03377387
- Testing
- Capecitabine, Neratinib, EORTC QLQ - BR23, EQ-5D-5L, EORTC QLQ-C30
- Where
- 10 sites in United States
- Volunteers
- 34 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer, Breast Tumors
Re-expression of ER in Triple Negative Breast Cancers
Patients are being asked to take part in this study because they have metastatic breast cancer that is triple negative (does not express estrogen receptor (ER), progesterone receptor (PR) or HER2).
- Conditions
- Breast Cancer, Breast Tumors, Breast Neoplasms
- Trial name
- NCT01194908
- Testing
- Decitabine, LBH589, Tamoxifen
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Emory University
Breast Cancer, Arthralgia
Androgen Therapy for Breast Cancer Patients With Aromatase Inhibitor Induced Side-Effects
The purpose of this study is to evaluate whether increasing blood levels of androgen can reduce some of the side-effects of anti-estrogen therapy (Arimidex)
- Conditions
- Breast Cancer, Arthralgia, Osteoporosis
- Trial name
- ART2 (NCT00497458)
- Testing
- Testosterone
- Where
- Australia
- Volunteers
- 90 people
- Sponsor
- Havah Therapeutics Pty Ltd
Locally Advance Breast Cancer (LABC), Metastatic Breast Cancer (MBC)
A Phase Ib/II Study of BEZ235 and Trastuzumab in Patients With HER2-positive Breast Cancer Who Failed Prior to Trastuzumab
This is a prospective, multi-center, open-label, phase Ib/ II study (two parts) with patients that have locally advanced or metastatic HER2+ breast cancer.
- Trial name
- NCT01471847
- Testing
- BEZ235 + Trastuzumab Phase l/Phase ll), Lapatinib + Capecitabine (Phase II)
- Where
- 3 sites in Spain, United Kingdom
- Volunteers
- 5 people
- Sponsor
- Novartis Pharmaceuticals
Breast Cancer
Laboratory-Treated T Cells After Second-Line Chemotherapy in Treating Patients With HER2/Neu-Negative Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT01022138
- Testing
- HER2Bi-armed activated T cells, Cyclophosphamide, Laboratory biomarker analysis
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Metastatic Breast Cancer
Phase II Study of GTx024 in Women With Metastatic Breast Cancer
The primary efficacy analysis will be the clinical benefit at 6 months as measured by a modified Response Evaluation Criteria in Solid Tumors RECIST classification.
- Trial name
- NCT01616758
- Testing
- GTx-024 9mg
- Where
- 4 sites in United States
- Volunteers
- 22 people
- Sponsor
- GTx
Metastatic Breast Cancer, Recurrent Breast Cancer
VEGF Trap in Treating Patients With Metastatic Breast Cancer
This phase II trial is studying how well VEGF Trap works in treating patients with metastatic breast cancer. VEGF Trap may stop the growth of tumor cells by blocking blood flow to the tumor
- Conditions
- Metastatic Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
- Trial name
- NCT00369655
- Testing
- ziv-aflibercept
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
ABI-007 and Bevacizumab in Treating Women With Recurrent or Metastatic Breast Cancer
RATIONALE: Drugs used in chemotherapy, such as ABI-007, work in different ways stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00404404
- Testing
- bevacizumab, paclitaxel albumin-stabilized nanoparticle formulation
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Premiere Oncology
Breast Cancer
Multi-catheter High Dose Rate (HDR) Breast Brachytherapy
Breast conservation therapy (BCT) is now widely accepted as a treatment option for most women with Stage I and II invasive breast cancer and most patients with ductal carcinoma in situ (DCIS).
- Trial name
- NCT00214149
- Testing
- brachytherapy
- Where
- United States
- Volunteers
- 127 people
- Sponsor
- University of Wisconsin, Madison
Breast Cancer
A Phase II Study of Radiation Therapy to Treat Refractory Breast Cancer
For locally advanced or recurrent metastatic breast cancer that is resistant to systemic therapy, radiotherapy (RT) may be considered as the preferred treatment option when the lesion is unresectable, or the patient is not…
- Trial name
- NCT07672743
- Testing
- Radical dose radiotherapy
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Breast Cancer Brain Metastases
Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.
This study evaluated the safety and efficacy of SPH4336 in combination with endocrine therapy in breast cancer Patients with brain metastases.
- Trial name
- NCT05872347
- Testing
- SPH4336 Tablets
- Where
- 25 sites in China
- Volunteers
- 52 people
- Sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd
Advanced Breast Cancer, HER2/Neu Negative
Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors
The aim of this single-arm phase 2 clinical trial is to evaluate the anti-cancer activity of Talazoparib (also known as BMN 673) in patients with advanced breast cancer with specific genetic or tumor genomic alterations.
- Conditions
- Advanced Breast Cancer, HER2/Neu Negative, Triple-Negative Breast Cancer
- Trial name
- NCT02401347
- Testing
- Talazoparib Tosylate
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Melinda Telli
Breast Cancer
Study of Biweekly Capecitabine Dosing With Bevacizumab for the Treatment of Metastatic Breast Cancer Based Upon the Norton-Simon Mathematical Model
The purpose of this study is to find out what effects (both good and bad) that capecitabine has on you and your breast cancer when given in a novel schedule in combination with the antibody therapy, bevacizumab.
- Trial name
- NCT00468585
- Testing
- Capecitabine, Bevacizumab
- Where
- 5 sites in United States
- Volunteers
- 62 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Advanced Breast Cancer
Sacituzumab Govitecan Plus Bevacizumab in Metastatic TNBC
This is a single-arm, multicenter, Phase II clinical study aiming to explore the efficacy and safety of Sacituzumab Govitecan combined with Bevacizumab as a second-line or later treatment for patients with metastatic…
- Trial name
- NCT07359404
- Testing
- Sacituzumab Govitecan (SG), Bevacizumab
- Where
- China
- Volunteers
- 60 people
- Sponsor
- YING FAN
Breast Cancer
Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Women With Locally Recurrent or Metastatic Breast Cancer
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming…
- Trial name
- NCT00088985
- Testing
- therapeutic autologous dendritic cells, trastuzumab, vinorelbine ditartrate
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Advanced High-grade Ovarian Cancer, Triple Negative Breast Cancer
Study of the Efficacy, Safety and Pharmacokinetics of Pamiparib (BGB-290) in Participants With Advanced Solid Tumors
This study is designed to evaluate the safety, tolerability, PKharmacokinetic profile and treatment effect of pamiparib in Chinese participants with advanced high-grade ovarian cancer (including fallopian cancer or primary…
- Trial name
- NCT03333915
- Testing
- Pamiparib
- Where
- 6 sites in China
- Volunteers
- 128 people
- Sponsor
- BeiGene
Breast Cancer, Neutropenia
Filgrastim or Pegfilgrastim in Preventing Neutropenia in Women Receiving Chemotherapy Following Surgery for Breast Cancer
RATIONALE: Colony-stimulating factors, such as filgrastim or pegfilgrastim, may increase the number of immune cells found in bone marrow or peripheral blood and may help a person's immune system recover from the side effects of…
- Trial name
- NCT00030758
- Testing
- filgrastim, pegfilgrastim
- Where
- 32 sites in United Kingdom
- Volunteers
- 816 people
- Sponsor
- Anglo Celtic Cooperative Oncology Group
HER2-positive Breast Cancer
Capecitabine in HER-2 Positive Breast Cancer With Pathologic Residual Tumors After Preoperative Chemotherapy
This study is designed to investigate the efficacy and safety of capecitabine, as a postoperative adjuvant chemotherapy, for HER-2 positive breast cancer patients who have pathologic residual cancer cells after the preoperative…
- Trial name
- NCT03684863
- Testing
- Capecitabine
- Volunteers
- 200 people
- Sponsor
- Shandong Cancer Hospital and Institute
Breast Cancer
HER-2 Protein Vaccine in Treating Women With Breast Cancer
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Phase I trial to study the effectiveness of HER-2 protein vaccine in treating women who have breast cancer.
- Trial name
- NCT00068614
- Testing
- HER-2/neu peptide vaccine
- Where
- United States
- Sponsor
- Case Comprehensive Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.